NuCana's NUC-3373 Shows Promise in Cancer Treatment

TipRanksNov 12 10:41 ET

NuCana Shares Results For Cancer Therapy, Sees Partial Responses In Phase 1b/2 Study

BenzingaNov 11 07:03 ET

Express News | NuCana Announces Encouraging Initial Data From Phase 1B/2 Modular Study of Nuc-3373 in Combination With Pembrolizumab or Docetaxel

ReutersNov 11 07:00 ET

NuCana Announces Encouraging Initial Data From Phase 1b/2 Modular Study of NUC-3373 in Combination With Pembrolizumab or Docetaxel

GlobeNewswireNov 11 07:00 ET

Truist Financial Sticks to Their Buy Rating for Nucana (NCNA)

TipRanksOct 16 03:00 ET · Ratings

Truist Slashes Price Target on NuCana to $20 From $150 Amid Discontinuation of NUC-3373, Keeps Buy Rating

MT NewswiresOct 15 07:54 ET · Ratings